{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T20:11:00Z","timestamp":1788379860111,"version":"build-2803163510"},"reference-count":49,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,23]],"date-time":"2025-11-23T00:00:00Z","timestamp":1763856000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/501100006044","name":"Astellas Pharma Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006044","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Br J Clin Pharmacol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>Treatment with enzalutamide in prostate cancer is challenging due to its high potential for drug\u2013drug interactions, particularly in the typically older population of patients with frequent comorbidities treated with multiple drugs, such as anticoagulants. While low molecular weight\u2010heparin can be safely combined with enzalutamide, the safety of combining enzalutamide with more convenient oral anticoagulants remains uncertain. The objective of this study was to assess whether a drug\u2013drug interaction exists between enzalutamide and edoxaban.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A prospective, multicentre, two\u2010arm parallel study was performed in men with prostate cancer who are treated with edoxaban, with and without enzalutamide. Plasma concentrations of edoxaban were measured at steady state. Pharmacokinetic (PK) parameters were calculated using non\u2010compartmental analysis. Geometric mean ratios (GMR) of the area under the plasma concentration time curve over one dosing interval (AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      ) were calculated. No clinically relevant interaction was defined if 90% of the confidence interval (CI) of the GMR was within the range of 0.8\u20131.25.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Sixteen patients with prostate cancer using edoxaban (eight patients with enzalutamide and eight patients without enzalutamide) were enrolled. The exposure of edoxaban was similar between patients treated with or without enzalutamide, however the 90% CI fell outside of the 0.8\u20131.25 range (AUC\n                      <jats:sub>0\u201324h<\/jats:sub>\n                      GMR 1.03; 90% CI 0.78\u20131.35).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The average exposure of edoxaban was not affected by enzalutamide. However, bioequivalence could not be established due to the broader than anticipated CI. Despite this, the larger variability in edoxaban exposure is not expected to be clinically relevant, supporting the safe co\u2010administration of both drugs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/bcp.70369","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T01:14:02Z","timestamp":1763946842000},"page":"1117-1125","source":"Crossref","is-referenced-by-count":1,"title":["Effect of enzalutamide on anticoagulant therapy with edoxaban in patients with prostate cancer"],"prefix":"10.1002","volume":"92","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-4204-5346","authenticated-orcid":false,"given":"Catharina J. P.","family":"Op 't Hoog","sequence":"first","affiliation":[{"name":"Department of Pharmacy Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niven","family":"Mehra","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anouk","family":"van Kleef","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diederik M.","family":"Somford","sequence":"additional","affiliation":[{"name":"Department of Urology Canisius Wilhelmina Hospital  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van Oort","sequence":"additional","affiliation":[{"name":"Department of Urology Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex L. T.","family":"Imholz","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology Deventer Hospital  Deventer The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Hamberg","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine Franciscus Gasthuis &amp; Vlietland  Rotterdam The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1553-178X","authenticated-orcid":false,"given":"Nielka P.","family":"van Erp","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3041-6774","authenticated-orcid":false,"given":"Emmy","family":"Boerrigter","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Radboud University Medical Center  Nijmegen The Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,23]]},"reference":[{"key":"e_1_2_11_2_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Public assessment report enzalutamide. European Medicines Agency (EMA).2013and updates."},{"key":"e_1_2_11_3_1","unstructured":"European Medicines Agency (EMA).Enzalutamide (Xtandi): summary of product characteristics.2013and updates."},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1405095"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800536"},{"key":"e_1_2_11_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1207506"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1177\/1756287213490054"},{"key":"e_1_2_11_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13425"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100283\u20101"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13229"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JOP.2017.022004"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557\u2010023\u201007453\u20100"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10928\u2010023\u201009867\u20107"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2010.08.006"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(10)70038\u20103"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470\u20102045(19)30336\u20105"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2019.11.007"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711948"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehaa612"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehz405"},{"key":"e_1_2_11_21_1","unstructured":"European Medicines Agency (EMA).Apixaban (Eliquis): summary of product characteristics.2011and updates."},{"key":"e_1_2_11_22_1","unstructured":"European Medicines Agency (EMA).Rivaroxaban (Xarelto): summary of product characteristics.2008and updates."},{"key":"e_1_2_11_23_1","unstructured":"European Medicines Agency (EMA).Dabigatran (Pradaxa): summary of product characteristics.2008and updates."},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.15420\/aer.2017.50.1"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100342\u20107"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.53"},{"key":"e_1_2_11_27_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.112.046888"},{"key":"e_1_2_11_28_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Public assessment report edoxaban. European Medicines Agency (EMA).2015."},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/bcp.13092"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2023.05.021"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10557\u2010023\u201007443\u20102"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261\u2010015\u20100298\u20102"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.1097\/FTD.0000000000000484"},{"key":"e_1_2_11_34_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).ICH M13A guideline on bioequivalence for immediaterelease solid oral dosage forms. In International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH) editor.2025."},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270009351883"},{"key":"e_1_2_11_36_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Guideline on the investigation of bioequivalence European Medicines Agency (EMA).2010."},{"key":"e_1_2_11_37_1","unstructured":"Center for Drug Evaluation and Research.Statistical approaches to establishing bioequivalence.Food and Drug Administration (FDA).2001."},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1081\/BIP\u2010120022772"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1111\/bph.16179"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40256\u2010013\u20100029\u20100"},{"key":"e_1_2_11_41_1","unstructured":"European Medicines Agency (EMA).Edoxaban (Lixiana): summary of product characteristics.2015and updates."},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140\u20106736(23)01055\u20103"},{"key":"e_1_2_11_43_1","unstructured":"Committee for Medicinal Products for Human Use (CHMP).Public assessment report talazoparib. European Medicines Agency (EMA).2023."},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.1124\/dmd.111.043877"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.21.12208"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1002\/psp4.12977"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11239\u2010019\u201002030\u20105"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262\u2010015\u20100271\u20105"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280\u2010020\u201004039\u20107"},{"key":"e_1_2_11_50_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.306"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70369","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/bcp.70369","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/bcp.70369","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T23:41:47Z","timestamp":1775432507000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1002\/bcp.70369"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,23]]},"references-count":49,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["10.1002\/bcp.70369"],"URL":"https:\/\/doi.org\/10.1002\/bcp.70369","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,23]]}}}